touchPODCAST

Expanding horizons for patients with Pompe disease: Using data to guide clinical practice

touchCONGRESS for touchNEUROLOGY

Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice.

Overview

•       Data reviews with Prof. Mozaffar,
•       Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below

Clinical themes

1. Clinical and real-world data on long-term outcomes in Pompe disease
2. Outcomes and impact of treatment switching in Pompe disease
3. Latest clinical data on current and emerging therapies in Pompe disease

The internationally renowned Pompe disease expert faculty

•       Prof. Tahseen Mozaffar, Irvine, CA, USA
•       Dr Jennifer L Cohen, Durham, NC, USA
•       Prof. Benedikt Schoser, Munich, Germany

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Amicus Therapeutics.

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.

For further information visit our website:

Expanding horizons for patients with Pompe disease Using data to guide clinical practice

touchCONGRESS for touchRESPIRATORY

Listen to world-leading expert Prof. Tahseen Mozaffar as he reviews key data on current and emerging treatment options for Pompe disease presented at the 29th Annual Congress of the World Muscle Society, and 21st Annual WORLDSymposium 2025. Prof. Mozaffar is then joined by fellow experts Dr Jennifer L Cohen and Prof. Benedikt Schoser to discuss how these data may apply in clinical practice.

Overview

•       Data reviews with Prof. Mozaffar,
•       Expert panel discussions with Prof. Mozaffar, Dr Cohen and Prof. Schoser on the themes below

Clinical themes

1. Clinical and real-world data on long-term outcomes in Pompe disease
2. Outcomes and impact of treatment switching in Pompe disease
3. Latest clinical data on current and emerging therapies in Pompe disease

The internationally renowned Pompe disease expert faculty

•       Prof. Tahseen Mozaffar, Irvine, CA, USA
•       Dr Jennifer L Cohen, Durham, NC, USA
•       Prof. Benedikt Schoser, Munich, Germany

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Amicus Therapeutics.

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.

For further information visit our website:

MDT perspectives on the importance of patient engagement in PARPi use - Video 3

touchMDT for touchONCOLOGY

Listen to experts Dr Alicia Morgans, Dr Grace Cullen, and patient advocate, Mr Tony Collier, discuss the importance and practicalities of engaging patients in their care and hear insights from the perspective of a patient advocate in relation to the use of PARP inhibitors.

The multidisciplinary team and patient advocate:

Medical oncologist – Dr Alicia Morgans
Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Nurse practitioner – Dr Grace Cullen

John D. Dingell VA Medical Center, Detroit, Michigan, USA

Patient Advocate – Mr Tony Collier
Tackle Prostate Cancer, London, UK

This touchPODCAST is for HCPs outside of the UK only.

This activity is supported by an independent medical education funding request from AstraZeneca.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/

 

MDT perspectives on understanding precision medicine to guide PARPi use in mCRPC - Video 2

touchMDT for touchONCOLOGY  

Somatic and germline testing are key in managing metastatic castration-resistant prostate cancer (mCRPC). Listen as Prof. Albrecht Stenzinger shares his perspectives as a pathologist with Dr Alicia Morgan and Dr Grace Cullen.  

The multidisciplinary team:

Medical oncologist – Dr Alicia Morgans
Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Nurse practitioner – Dr Grace Cullen
John D. Dingell VA Medical Center, Detroit, Michigan, USA

Pathologist – Prof. Albrecht Stenzinger
University of Heidelberg, Heidelberg, Germany

This touchPODCAST is for HCPs outside of the UK  only.

This activity is supported by an independent medical education funding request from AstraZeneca.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/

MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC - Video 1

touchMDT for touchONCOLOGY

MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC

Experts Dr Alicia Morgans and Dr Grace Cullen share insights into using evidence to guide practice and shared decision-making with patients with metastatic castration-resistant prostate cancer (mCRPC).

The multidisciplinary team:

Medical oncologist – Dr Alicia Morgans
Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Nurse practitioner – Dr Grace Cullen
John D. Dingell VA Medical Center, Detroit, Michigan, USA

This touchPODCAST is for HCPs outside of the UK  only.

This activity is supported by an independent medical education funding request from AstraZeneca.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitors-in-mcrpc/

The next frontier in managing obesity and T2D: The role of novel combinations for touchCARDIO

touchEXPERT OPINIONS for touchCARDIO

Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D).

The experts

• Dr Sue Pedersen, University of Calgary, Calgary, Canada
• Prof. Carel le Roux, University College Dublin, Dublin, Ireland
• Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA

This touchPODCAST is for healthcare professionals outside of the USA and UK.

This activity is funded by an independent medical education grant from Novo Nordisk A/S.

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider. 

For further information visit our website: 

www.touchCARDIO.com

The next frontier in managing obesity and T2D: The role of novel combinations for touchENDOCRINOLOGY

touchEXPERT OPINIONS for touchENDOCRINOLOGY

Listen to three experts discuss the rationale behind glucagon-like peptide-1 (GLP-1)-based combination therapies and review the latest clinical evidence for these novel combinations. The expert faculty will provide their insights on what these combination treatments may mean for the future management of obesity with or without type 2 diabetes (T2D).

The experts

• Dr Sue Pedersen, University of Calgary, Calgary, Canada
• Prof. Carel le Roux, University College Dublin, Dublin, Ireland
• Dr Donna Ryan, Pennington Biomedical Research Center, Baton Rouge, LA, USA

This touchPODCAST is for healthcare professionals outside of the USA and UK.

This activity is funded by an independent medical education grant from Novo Nordisk A/S.

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider. 

For further information visit our website: 

www.touchENDOCRINOLOGY.com

From clinical trials to clinical practice: Applying CDK4/6 inhibitors in HR+/HER2– early breast cancer

touchEXPERT OPINIONS for touchONCOLOGY

Listen to three experts in breast cancer as they provide insights into the current guideline recommendations for the use of targeted therapy in patients with HR+/HER2– early breast cancer, evaluate the latest data for CDK4/6 inhibitors in this patient population and consider how to maximize the potential of these agents through risk stratification and safety considerations.

 

The experts

• Prof. Carlos Barrios: Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
• Prof. Dr. med. Peter Fasching: University Hospital Erlangen and Comprehensive Cancer Center, Erlangen-EMN, Germany
• Dr Sonia Pernas: Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

 

This touchPODCAST is for healthcare professionals outside of the UK and the USA.

This activity is funded by an independent medical education grant from Novartis.

This activity is provided by touchIME.

 

For further information visit our website: 

www.touchONCOLOGY.com

Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals

touchIN CONVERSATION for touchONCOLOGY

Listen to a paediatrician specializing in adolescent medicine and a general practitioner specializing in sexual health as they address healthcare professionals' questions on HPV vaccination. They provide insights into the burden of HPV-related oncological and non-oncological diseases, appropriate vaccination schedules for specific patient groups, and strategies to improve vaccine uptake across various healthcare settings.

The experts

• Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA
• Dr Marc Steben, HPV Global Action and Université de Montréal, Canada

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. 

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchoncologyime.org/in-conversation-improving-hpv-vaccine-uptake/

Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals

touchIN CONVERSATION for touchINFECTIOUS DISEASES

Listen to a paediatrician specializing in adolescent medicine and a general practitioner specializing in sexual health as they address healthcare professionals' questions on HPV vaccination. They provide insights into the burden of HPV-related oncological and non-oncological diseases, appropriate vaccination schedules for specific patient groups, and strategies to improve vaccine uptake across various healthcare settings.

The experts

• Dr Barbara Moscicki, UCLA Health and University of California, Los Angeles, CA, USA
• Dr Marc Steben, HPV Global Action and Université de Montréal, Canada

This touchPODCAST is for HCPs outside of the UK only.

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC. 

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.

For further information visit our website: 

https://touchinfectiousdiseasesime.org/in-conversation-improving-hpv-vaccine-uptake/